

DAFTAR PUSTAKA

- Almefty, R, 2017, Meningiomas, dalam Youmans & Winn Neurological Surgery, diedit oleh Winn, H. R., New York : Elsevier, hal. 4692.
- Arrieta, O, 2020, “Association between CD47 Expression, Clinical Characteristic and Prognosis in Patient with Advanced Non-Small Cell Lung Cancer”, *Cancer Medi.* 2020;9:2390-2402. <https://doi.org/10.1002/cam4.2882>
- Azene EM, Gai QW, Tabar SP, Morrison AL, Meisenberg B. Metastasis of a histologically benign-appearing meningioma to the iliac bone. *J Clin Oncol* 2008;26(28):4688–4690
- Barclay AN, Van den Berg TK. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. *Annu Rev Immunol.* 2014;32:25-50.
- Barclay AN. Signal regulatory protein alpha (SIRPalpha)/CD47 interaction and function. *Curr Opin Immunol.* 2009;21(1):47-52.
- Braster R, O’toole T, Van Egmond M. Myeloid cells as effector cells for monoclonal antibody therapy of cancer. *Methods.* 2014;65(1):28-37.
- Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. *Nat Rev Cancer.* 2015;15(10):577-592.
- Central Brain Tumor Registry of the United States. 2009–2010 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in Eighteen States in 2002–2006. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2009. <http://www.cbtrus.org>
- Christensen HC, Kosteljanetz M, Johansen C. Incidences of gliomas and meningiomas in Denmark, 1943 to 1997. *Neurosurgery.* (2003) 52:1327–33; discussion 1333–24. doi: 10.1227/01.NEU.00000064802.46759.53
- Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of intracranial meningioma. *Neurosurgery* 2005;57(6):1088–1095, discussion 1088–1095
- Claus E. B., 2011, Epidemiology of Meningiomas, dalam Al-Mefty’s Meningiomas, Diedit oleh Conerly, K., New York: Thieme Medical Publisher, hal. 35.
- Garzon-Muvdi, T., Bailey, D., Pernik., M., Pan, E. Basis for Immunotherapy for Treatment of Meningiomas. *Front. Neurology.* doi: 10.3889. 2020.
- Garzon-Muvdi T, Yang W, Lim M, Brem H, Huang J. Atypical and anaplastic meningioma: outcomes in a population based study. *J Neurooncol.* (2017) 133:321–30. doi: 10.1007/s11060-0172436-6
- Gunadi, S., Suryanti, S., and Yohana, R. (2018) ‘The Distribution of Meningioma in Dr. Hasan Sadikin General Hospital Bandung Period 2010-2013’, *Althea Medical Journal*, 5(3), pp. 157-160. doi: 10.1580/amj.v5n3.1062.
- Gutmann DH, Donahoe J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. *Hum Mol Genet* 2000;9(10): 1495–1500.
- Huang, M.C, 2011, Anatomy and Biology of Leptomeninges, dalam Al-Mefty’s Meningiomas, Diedit oleh Conerly, K., New York: Thieme Medical Publisher, hal. 25.

- James MF, Han S, Polizzano C, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. *Mol Cell Biol* 2009;29(15):4250–4261
- James MF, Stivison E, Beauchamp R, et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. *Mol Cancer Res* 2012;10(05):649–659
- Jiang, Z., Sun, H., Yu, J., Tian, W., Song, Y. Targeting CD47 for cancer immunotherapy. *Journal of Hematology and Oncology*. (2021). <https://doi.org/10.1186/s13045-021-01197-w>
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol.* (2007) 114:97–109. doi: 10.1007/s00401-007-0243-4
- Matozaki T, Murata Y, Okazawa H, Ohnishi H. Functions and molecular mechanisms of the CD47–SIRP α signalling pathway. *Trends Cell Biol.* 2009;19(2):72-80.
- Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, Larvie M, Curry WT, Barker FG II, et al. Benign meningiomas (WHO Grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. *J Neurosurg.* (2016) 124:106–14. doi: 10.3171/2015.1.JNS142228
- Marosi, C., Hassler, M., Roessler, K., Reni, M., Sant, M., Mazza, E. and Vecht, C. (2008) ‘Meningioma’, *Critical Review in Oncology/Hematology*. doi: 10.1016/j.citrevonc.2008.01.010.
- Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. *J Neurooncol* 2010;99(03):379–391
- Murata Y, Kotani T, Ohnishi H, Matozaki T. The CD47–SIRP α signalling system: its physiological roles and therapeutic application. *The Journal of Biochemistry.* 2014;155(6):335-344.
- Murata Y, Saito Y, Kotani T, Matozaki T. CD 47- signal regulatory protein α signaling system and its application to cancer immunotherapy. *Cancer Sci.* 2018;109(8):2349-2357.
- Ng, H. K., & Chen, L. (1998). Apoptosis is associated with atypical or malignant change in meningioma. An in situ labelling and immunohistochemical study. *Histopathology*, 33(1), 64-70. <https://doi.org/10.3390/biomedicines9030319>
- O'Donnell JS, Massi D, Teng MW, Mandala M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Paper presented at: Seminars in cancer biology 2018.
- Orozco-Morales M, Aviles-Salas A, Hernandez-Pedro, Catalan R, et al. Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors. *Journal of Immunology Research*, 2021. <https://doi.org/10.1155/2021/6632249>
- Pant, I., Chaturvedi, S., Sarma, P., & Singh, G. (2021). Histopathological Mapping of Meningiomas : A 10-year Retrospective Analysis. *Indian Journal of Neurosurgery*, 10(03), 203-209. <https://doi.org/10.1055/s-0040-1718990>

- Perry A, Cai DX, Scheithauer BW, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. *J Neuropathol Exp Neurol* 2000;59(10):872–879
- Psaras T, Pantazis G, Steger V, Meyermann R, Honegger J, Beschorner R. Benign meningioma developing late lung metastases: case report and review of the literature. *Clin Neuropathol* 2009;28(06):453–459
- Sahm F, Schrimpf D, Olar A, et al. TERT promoter mutations and risk of recurrence in meningioma. *J Natl Cancer Inst* 2015;108 (05):377
- Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. *Lancet Oncol.* (2017) 18:682–94.doi: 10.1016/S1470-2045(17)30155-9
- Senol, O., Schaaij-Visser, TBM., Erkan, EP., Dorfer, C., Lewandrowski, G., Pham, TV., et al. miR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth *in vivo*. *Oncogene* (2015) 34, 1790-1798. doi: 10.1038/onc.2014.120
- Sudo, T., Takahashi, Y., Sawada, G., Uchi, R., Mimori, K., Akagi, Y. Significance of CD47 expression in gastric cancer. *Oncology Letters*, 2017. doi : 10.3892/ol.2017.6257
- Sun SQ, Cai C, Murphy RK, Dewees T, Dacey RG, Grubb RL, et al. Management of atypical cranial meningiomas, part 2: predictors of progression and the role of adjuvant radiation after subtotal resection. *Neurosurgery.* (2014) 75:356–63; discussion:363. doi: 10.1227/NEU.0000000000000462
- Sun SQ, Hawasli AH, Huang J, Chicoine MR, Kim AH. An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. *Neurosurg Focus.* (2015) 38:E3. doi:10.3171/2015.1.FOCUS14757
- Ueki K, Wen-Bin C, Narita Y, Asai A, Kirino T. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. *Cancer Res* 1999;59(23): 5995–5998
- Wang, N., Osswald, M. Meningiomas: Overview and new directions in therapy. *Semin Neurol* 2018;38:112-120
- Winn, R. (2017) ‘Youmann & Winn Neurological Surgery’, in Youman & Winn *Neurological Surgery*. doi: 10.1016/j.radonc.2014.12.002.
- Willingham, S., Volkmer, JP., Gentles, AJ., Sahoo, D., Dalerba, P., Mitra, SS., et al. The CD47-signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumor. *PNAS.* (2012) www.pnas.org/cgi/doi/10.10173/pnas
- Yanagita T, Murata Y, Tanaka D, et al. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. *JCI insight.* 2017;2(1).
- Yuan, J., He, H., Chen, C., Wu, J., Rao, J., Yan, H. Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients. *Cancer Cell International.* (2019). <https://doi.org/10.1186/s12935-019-0957-0>

Zhao, Y., Yu., X., Tang, H., Han, R., Wang, X., Wang J., et al. Micro RNA-200a promotes phagocytosis of macrophages and suppressed cell proliferation, migration, and invasion in nasopharyngeal carcinoma by targeting CD47. *BioMed Research International*. (2020).
<https://doi.org/10.1155/2020/3723781>